Today announced it has bought the MassCode Tag technology from Eurofins MWG Operon.

Dr. Lipkin, along with Dr. Thomas Briese, associate professor of Epidemiology at Columbia, have used this technology within their research to further innovative methods of pathogen identification and discovery for unexplained respiratory attacks, viral hemorrhagic fevers, and meningoencephalitis. The patents Agilent offers purchased cover differing aspects of the MassCode Tag technology and so are valid in 34 countries like the United States, United Kingdom, Japan, and China.. Agilent Technologies acquires MassCode Tag technology from Eurofins MWG Operon Agilent Technology Inc. today announced it has bought the MassCode Tag technology from Eurofins MWG Operon, a division of Eurofins. The MassCode is included by The purchase trademarks and intellectual real estate, including four groups of patents.

Positive results from this Phase 2b trial had been also offered in July 2015 during the Past due Breaking Novel Therapeutics Session at the Alzheimer's Association International Conference . This is promising particularly, given having less effective therapies and novel treatment options in development for this devastating disease, stated Kees Been, president and chief executive officer of EnVivo Pharmaceuticals. We are planning to advance EVP-6124 into a Phase 3 scientific trial in schizophrenia this fall and another Phase 3 trial system in Alzheimer's disease in 2013. This continued improvement positions EVP-6124 for potential patient impact and benefit and moves us toward our objective of becoming a fully integrated biotechnology company.Positive results from this Phase 2b trial had been also offered in July 2015 during the Past due Breaking Novel Therapeutics Session at the Alzheimer's Association International Conference . This is promising particularly, given having less effective therapies and novel treatment options in development for this devastating disease, stated Kees Been, president and chief executive officer of EnVivo Pharmaceuticals. We are planning to advance EVP-6124 into a Phase 3 scientific trial in schizophrenia this fall and another Phase 3 trial system in Alzheimer's disease in 2013. This continued improvement positions EVP-6124 for potential patient impact and benefit and moves us toward our objective of becoming a fully integrated biotechnology company.